- Email: [email protected]
Nutrient composition of evening meals is associated with raised glycosylated haemoglobin levels in the 1946 British Birth Cohort
1174
Abstracts / Appetite 58 (2012) 1169–1176
Experimental study to investigate the impact of a patented fibre complex containing CM3 alginate (Biogenate complexTM; APPEsatTM) on food intake and appetite ratings in women. J.A. HARROLD, J. REES, R. YARD, N. WILLIAMS, G. HUGHES, E.J. BOYLAND, J.C.G. HALFORD. The Kissileff Laboratory for Ingestive Behaviour, Department of Experimental Psychology, University of Liverpool, Liverpool L69 7ZA, UK. [email protected] Various commercial medical devices are purported to produce beneficial effects on appetite. However, their effects on energy intake remain to be established. In the present study the impact of a patented fibre complex containing CM3 alginate (Biogenate ComplexTM; APPEsatTM) on appetite and food intake were examined in a double blind, placebo controlled, cross-over design. On two study days 17 healthy normal to slightly overweight women consumed a fixed load breakfast followed at four hour intervals by an ad libitum lunch and an ad libitum dinner. They were administered the doses of Appesat (3 tablets) or placebo (3 tablets) with 250 ml of water 30 min before each of the three meals. Appetite was measured across the day using visual analogue scales and energy intake was measured at each ad libitum meal. Results showed no impact of APPEsat on either gram or energy intake at each individual ad libitum meal or over the duration of the study day (917.76 72.58 g vs 917.42 74.17 g; 1741.51 133.18 kcal vs 1753.74 127.46 kcal; placebo vs APPEsat; mean SEM). Hunger and desire to eat were found to be significantly greater and fullness and satisfaction were found to be significantly lower, at certain time points, in the APPEsat condition. No significant effect was found for prospective consumption. These results question the suitability of short-term CM3 alginate treatment as a means of appetite suppression in the current study population, which reflects its intended use. Previously reported satiating effects of APPEsat utilised non-standard methodology. Previously reported APPEsat induced weight loss may be mediated by a mechanism other than reductions in energy intake. However, effects on intake may become apparent after repeated dosing or when tested in an obese population. doi:10.1016/j.appet.2012.02.032
Experimental study to investigate the impact of a patented soluble plant fibre complex Omtec19Ò (Obesimede) on food intake and appetite ratings in women. J.A. HARROLD, J. JOHNSON, K. MATHER, N. WILLIAMS, G. HUGHES, E.J. BOYLAND, J.C.G. HALFORD. The Kissileff Laboratory for Ingestive Behaviour, Department of Experimental Psychology, University of Liverpool, Liverpool L69 7ZA, UK. [email protected] Various commercial medical devices are purported to produce beneficial effects on appetite. However, their effects on energy intake remain to be established. In the present study the impact of a patented soluble plant fibre complex Omtec19Ò (Obesmide) on appetite and food intake were examined in a double blind, placebo controlled, cross-over design. On two study days 17 healthy normal to slightly overweight women consumed a fixed load breakfast followed at 4 h intervals by an ad libitum lunch and an ad libitum dinner. They were administered the doses of Obesimed (2 tablets) or placebo (2 tablets) with 500 ml of water 1 h before each of the three
meals. Appetite was measured across the day using visual analogue scales and energy intake was measured at each ad libitum meal. Results showed no impact of Obesimed on either gram or energy intake at each individual ad libitum meal or over the duration of the study day (966.99 51.27 g vs 1010.66 67.10 g; 1685.45 91.02 kcal vs 1789.92 111.95 kcal; placebo vs obesimed; mean SEM). However, a trend for a main effect on hunger and a significant main effect on satisfaction were observed. Obesimed significantly reduced hunger pre dinner and increased satisfaction 2 h post lunch. No significant effects were found for prospective consumption, fullness or desire to eat at any time point. These results question the suitability of short-term Obesimed treatment as a means of appetite suppression in the current study population. Previously reported Obesimed induced weight loss (unpublished data) may be mediated by a mechanism other than reductions in energy intake. Alternatively, effects on intake may become apparent after repeated dosing or when tested in an obese population. doi:10.1016/j.appet.2012.02.033
Nutrient composition of evening meals is associated with raised glycosylated haemoglobin levels in the 1946 British Birth Cohort. S. ALMOOSAWI, C. PRYNNE, R. HARDY, A.M. STEPHEN. Elsie Widdowson Laboratory, MRC Human Nutrition Research, 120 Fulbourn Road, Cambridge CB1 9NL, UK. [email protected] The time of eating and nutrient composition of meals is increasingly recognised to be associated with multiple metabolic abnormalities. However, few studies have described the association between time and nutrient composition of eating occasions and long-term diabetes risk. This study examined the association between time and nutrient composition of eating occasions and glycosylated haemoglobin (HbA1c) in the 1946 British Birth Cohort. The study included 1069 survey members who completed dietary assessment at ages 43 (1989) and 53 years (1999) and for whom data on HbA1c at age 53 years (1999) was available. Diet was assessed using 5 d estimated diaries which were divided into seven time slots: breakfast, mid-morning, lunch, mid-afternoon, dinner, late evening and extra. Individuals above the top quintile of glycosylated haemoglobin or those on medication for diabetes were deemed to have raised HbA1c. The association between time and nutrient composition of eating occasions at age 43 years and elevated HbA1c at age 53 years was assessed using multivariate nutrient density models after adjustment for sex, social class, smoking, region, alcohol intake, exercise, body mass index and waist circumference. There were 240 cases of high HbA1c at age 53. Increasing fat intake at dinner at the expense of carbohydrate was related to higher odds ratio (OR) of having raised HbA1c (OR = 1.13; 95% CI = 1.01–1.26; P = 0.036). Substituting 5% of energy from fat late in the evening for a similar amount of energy from carbohydrate (OR = 1.06; 95% CI = 1.01–1.11; P = 0.023) or protein (OR = 1.05; 95% CI = 1.00–1.10; P = 0.043) also predicted higher HbA1c levels. In conclusion, greater fat intake in the evenings predicts high long-term HbA1. doi:10.1016/j.appet.2012.02.034
Abstracts / Appetite 58 (2012) 1169–1176
Experimental study to investigate the impact of a patented fibre complex containing CM3 alginate (Biogenate complexTM; APPEsatTM) on food intake and appetite ratings in women. J.A. HARROLD, J. REES, R. YARD, N. WILLIAMS, G. HUGHES, E.J. BOYLAND, J.C.G. HALFORD. The Kissileff Laboratory for Ingestive Behaviour, Department of Experimental Psychology, University of Liverpool, Liverpool L69 7ZA, UK. [email protected] Various commercial medical devices are purported to produce beneficial effects on appetite. However, their effects on energy intake remain to be established. In the present study the impact of a patented fibre complex containing CM3 alginate (Biogenate ComplexTM; APPEsatTM) on appetite and food intake were examined in a double blind, placebo controlled, cross-over design. On two study days 17 healthy normal to slightly overweight women consumed a fixed load breakfast followed at four hour intervals by an ad libitum lunch and an ad libitum dinner. They were administered the doses of Appesat (3 tablets) or placebo (3 tablets) with 250 ml of water 30 min before each of the three meals. Appetite was measured across the day using visual analogue scales and energy intake was measured at each ad libitum meal. Results showed no impact of APPEsat on either gram or energy intake at each individual ad libitum meal or over the duration of the study day (917.76 72.58 g vs 917.42 74.17 g; 1741.51 133.18 kcal vs 1753.74 127.46 kcal; placebo vs APPEsat; mean SEM). Hunger and desire to eat were found to be significantly greater and fullness and satisfaction were found to be significantly lower, at certain time points, in the APPEsat condition. No significant effect was found for prospective consumption. These results question the suitability of short-term CM3 alginate treatment as a means of appetite suppression in the current study population, which reflects its intended use. Previously reported satiating effects of APPEsat utilised non-standard methodology. Previously reported APPEsat induced weight loss may be mediated by a mechanism other than reductions in energy intake. However, effects on intake may become apparent after repeated dosing or when tested in an obese population. doi:10.1016/j.appet.2012.02.032
Experimental study to investigate the impact of a patented soluble plant fibre complex Omtec19Ò (Obesimede) on food intake and appetite ratings in women. J.A. HARROLD, J. JOHNSON, K. MATHER, N. WILLIAMS, G. HUGHES, E.J. BOYLAND, J.C.G. HALFORD. The Kissileff Laboratory for Ingestive Behaviour, Department of Experimental Psychology, University of Liverpool, Liverpool L69 7ZA, UK. [email protected] Various commercial medical devices are purported to produce beneficial effects on appetite. However, their effects on energy intake remain to be established. In the present study the impact of a patented soluble plant fibre complex Omtec19Ò (Obesmide) on appetite and food intake were examined in a double blind, placebo controlled, cross-over design. On two study days 17 healthy normal to slightly overweight women consumed a fixed load breakfast followed at 4 h intervals by an ad libitum lunch and an ad libitum dinner. They were administered the doses of Obesimed (2 tablets) or placebo (2 tablets) with 500 ml of water 1 h before each of the three
meals. Appetite was measured across the day using visual analogue scales and energy intake was measured at each ad libitum meal. Results showed no impact of Obesimed on either gram or energy intake at each individual ad libitum meal or over the duration of the study day (966.99 51.27 g vs 1010.66 67.10 g; 1685.45 91.02 kcal vs 1789.92 111.95 kcal; placebo vs obesimed; mean SEM). However, a trend for a main effect on hunger and a significant main effect on satisfaction were observed. Obesimed significantly reduced hunger pre dinner and increased satisfaction 2 h post lunch. No significant effects were found for prospective consumption, fullness or desire to eat at any time point. These results question the suitability of short-term Obesimed treatment as a means of appetite suppression in the current study population. Previously reported Obesimed induced weight loss (unpublished data) may be mediated by a mechanism other than reductions in energy intake. Alternatively, effects on intake may become apparent after repeated dosing or when tested in an obese population. doi:10.1016/j.appet.2012.02.033
Nutrient composition of evening meals is associated with raised glycosylated haemoglobin levels in the 1946 British Birth Cohort. S. ALMOOSAWI, C. PRYNNE, R. HARDY, A.M. STEPHEN. Elsie Widdowson Laboratory, MRC Human Nutrition Research, 120 Fulbourn Road, Cambridge CB1 9NL, UK. [email protected] The time of eating and nutrient composition of meals is increasingly recognised to be associated with multiple metabolic abnormalities. However, few studies have described the association between time and nutrient composition of eating occasions and long-term diabetes risk. This study examined the association between time and nutrient composition of eating occasions and glycosylated haemoglobin (HbA1c) in the 1946 British Birth Cohort. The study included 1069 survey members who completed dietary assessment at ages 43 (1989) and 53 years (1999) and for whom data on HbA1c at age 53 years (1999) was available. Diet was assessed using 5 d estimated diaries which were divided into seven time slots: breakfast, mid-morning, lunch, mid-afternoon, dinner, late evening and extra. Individuals above the top quintile of glycosylated haemoglobin or those on medication for diabetes were deemed to have raised HbA1c. The association between time and nutrient composition of eating occasions at age 43 years and elevated HbA1c at age 53 years was assessed using multivariate nutrient density models after adjustment for sex, social class, smoking, region, alcohol intake, exercise, body mass index and waist circumference. There were 240 cases of high HbA1c at age 53. Increasing fat intake at dinner at the expense of carbohydrate was related to higher odds ratio (OR) of having raised HbA1c (OR = 1.13; 95% CI = 1.01–1.26; P = 0.036). Substituting 5% of energy from fat late in the evening for a similar amount of energy from carbohydrate (OR = 1.06; 95% CI = 1.01–1.11; P = 0.023) or protein (OR = 1.05; 95% CI = 1.00–1.10; P = 0.043) also predicted higher HbA1c levels. In conclusion, greater fat intake in the evenings predicts high long-term HbA1. doi:10.1016/j.appet.2012.02.034